Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANAVEX2-73 extension in early Alzheimer's disease
NCT04314934Phase 3Completed
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Oct 2019
- Primary completion
- Jun 2024
- Modality
- Classical Binding Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of blarcamesine in Alzheimer's disease (AD), sponsored by Anavex Life Sciences Corp.. Started Oct 2019; status: completed.
02
Drugs
blarcamesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04314934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314934.